|
1. Hormones.
E-E Baulieu and Paul A.Kelly. Hermann
publishers1990)
2. Twenty-four
hours mean plasma testosterone concentration
decline in non premenopausal women. Zumoff
B, Strain GW,Miller LK, Rosner W. J Clin
Endocrinol Metab, 1995, 80:1429-1430
3. Consequences
of oral contraceptive troubles with decrease
of androgen ovarian
synthesis. Harrison’s
Principes de medicine interne – 331 :
Maladies de l’ovaire et de l’appareil
génital féminin: p. 1832-1833, 1988.
3.1. Effects
of oral contraceptives on breast epithelial
proliferation. Isaksson
E, von Schoultz E, Odlind V, Soderqvist G,
Csemiczky G, Carlstrom K, Skoog L, von
Schoultz B. Department
of Oncology, Radiumhemmet, Karolinska
Hospital, Stockholm, Sweden Breast
Cancer Res Treat2001 Jan;
65(2):163-169
3.2 Oral
contraceptive use as a risk factor for
premenopausal breast cancer: a
meta-analysis.
Kahlenborn C, Modugno
F, Potter
DM, Severs
WB. Mayo
Clin Proc. 2006
Oct;81(10):1290-302.
3.3. Effect of Depo-Medroxyprogesterone
Acetate on Breast Cancer Risk among Women 20
to 44 Years of Age. Christopher
I. Li, Elisabeth
F. Beaber, Mei
Tzu Chen Tang,Peggy
L. Porter, Janet
R.Daling, Kathleen
E. Malone. Cancer
Res; 72(8); 2028–35.2012
4. Impact
of Oral Contraceptives on Sex
Hormone-Binding Globulin and Androgen
Levels: A Retrospective Study in Women with
Sexual Dysfunction.Panzer et al. The
Journal of Sexual Medicine, January
2006;3:p.104-113
5. Risks
and benefits of estrogen plus progestin in
healthy postmenopausal women: principal
results From the Women's Health Initiative
randomized controlled trial. Rossouw
JE, Anderson GL, Prentice RL, LaCroix AZ,
Kooperberg C, Stefanick ML, Jackson RD,
Beresford SA, Howard BV, Johnson KC, Kotchen
JM, Ockene J; Writing Group for the Women's
Health Initiative Investigators. JAMA.
2002 Jul 17;288(3):321-33.
6. Promotional
tone in reviews of menopausal hormone
therapy after the Women's Health Initiative:
an analysis of published articles.Fugh-Berman
A, McDonald CP, Bell AM, Bethards EC,
Scialli AR.Department of Physiology and
Biophysics, Georgetown University Medical
Center, Washington, DC, USA.PLoS Med. 2011
Mar;8(3):e1000425. Epub 2011 Mar 15.
7.
Androgens and osteocalcin during the
menstrual cycle.
Massafra C, De Felice C, Agnusdei DP, Gioia
D, Bagnoli F. Department of Obstetrics and
Gynecology, University of Siena, Italy. J
Clin Endocrinol Metab. 1999 Mar;84(3):971-4
8.Testosterone measured by 10
immunoassays and by isotope-dilution gas
chromatography-mass spectrometry in sera
from 116 men,women, and children. Taieb
J, Mathian B, Millot F, Patricot MC, Mathieu
E, Queyrel N, Lacroix I, Somma-Delpero C,
Boudou P. Hormonology Laboratory, A. Béclère
Hospital, 92141 Clamart, France. Clinical
Chemistry 49, 1381-1395, 2003.
9. Androgen
levels in adult females: changes with age,
menopause, and oophorectorny. Davison
SL, Bell R, Donath S, Montalto JG, Davis SR.
J Clin Endocrinol Metab, 2005, 90:3847-53.
10. Androgen
glucuronides, instead of testosterone, as
the new markers of androgenic activity in
women.Labrie F, Bélanger A, Bélanger R
Bérubé R, Martel C, Cusan L, Gomez J, Candas
B, Castiel I, Chaussade V, Deloche C,
Leclaire J.. J Steroid Biochem Mol Biol,
2006, 99:182-188.
11. Wide
distribution of the serum
dehydroepiandrosterone and sex steroid
levels in postmenopausal women: role of the
ovary? Labrie
F, Martel C, Balser J. Endoceutics
Inc, Quebec City, Quebec, Canada. Menopause.2011
Jan: 18 (1):30-43.
12. Low
testosterone levels predict all-cause
mortality and cardiovascular events in
women: a prospective cohort study in German
primary care patients. Sievers
C, Klotsche J, Pieper L, Schneider HJ, März
W, Wittchen HU, Stalla GK, Mantzoros
C.Department of Endocrinology, Max Planck
Institute of Psychiatry, Kraepelinstrasse
2-10, Munich, Germany. Eur J Endocrinol.
2010 Oct;163(4):699-708. Epub 2010 Aug 4.
13. Higher
serum free testosterone concentration in
older women is associated with greater bone
mineral density, lean body mass, and total
fat mass: the cardiovascular health study. Rariy
CM, Ratcliffe SJ, Weinstein R, Bhasin S,
Blackman MR, Cauley JA, Robbins J, Zmuda JM,
Harris TB, Cappola AR. Division of
Endocrinology, University of Pennsylvania
School of Medicine, Philadelphia,
Pennsylvania 19104, USA. J Clin Endocrinol
Metab. 2011 Apr;96(4):989-96. Epub 2011 Feb
2.
14.Hormonal
Influences Upon Connective Tissue Changes of
Aging, SOBEL
H. and MARMORSTON J. Institute
for Medical Research, Cedars of Lebanon
Hospital, and the Depart-ment of
Biochemistry and Nutrition and the
Department of Medicine, University of
Southern
California, Los Angeles, California,in:
PINCUS G (ed. ) Recent Progress in Hormone
Research, vol. 14. Academic New York 1958.
15. Brain
levels of sex steroid hormones in men and
women during normal aging and in Alzheimer's
disease. Rosario
ER, Chang L, Head EH, Stanczyk FZ, Pike CJ. Davis
School of Gerontology, University of
Southern California, Los Angeles, CA 90089,
USA. Neurobiol
Aging. 2011 Apr;32(4):604-13. Epub 2009 May
9.
16 . La
pathologie obstructive congénitale de
l’uretère terminal. G.
Debled : p.
446- 452 ; Acta Urologica
Belgica,1971,39,371-465
17. High
Court Rejects Pfizer Hormone Therapy Lawsuit
Appeal
Date Published: Wednesday, June 22nd, 2011
The U.S. Supreme Court refused to hear a
Pfizer Inc. unit’s appeal of a $58 million
award in a case
against Premarin and Prempro menopause
drugs.
Three Nevada women who contracted breast
cancer after taking the company’s menopause
drugs
were awarded the amount in a 2007 case.
The rebuff leaves the amount as the largest
to be upheld on appeal in thousands of
hormonereplacement
drug suits. Over six million women took
Prempro and other menopause drugs before a
2002 study pointed out their links to
cancer. At one point Pfizer and his units
faced more than 10,000
claims, according to lawyers for former
users.
The Nevada Supreme Court concluded jurors
properly held Pfizer’s Wyeth unit
responsible for hiding
he breast-cancer
risks of Premarin and Prempro. The original
2007 case resulted in an award totaling
$134.1 million to Arlene Rowatt, Jeraldine
Scofield and Pamela Forrester. The trial
judge later
reduced the verdict to $57.6 million.
Yearly sales of Wyeth’s hormone‐replacement
drugs exceeded $2 billion before a 2002
study,
sponsored by the U.S. National Institutes of
Health, suggested that women using the
medicines had a
24 percent higher risk of breast cancer.
Pfizer, the world’s largest drug maker,
acquired Wyeth in 2009 settled a third of
the pending cases
over its Prempro menopause drug. The company
said last month that it set aside $772
million to
resolve claims over the medicine.
|
.jpg){kind=small}
.png){kind=small}
